Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Impact · against what's priced in

The article provides no new catalysts for Amgen or Johnson & Johnson, as the reported financial growth and risk profiles are already reflected in their current valuations. The mentioned revenue growth for Amgen and the diversified nature of J&J's business are already baseline assumptions for the market.

JNJ+0.00: Already priced in
The price assumes: The raised 2026 revenue guidance of $100.3–$101.3 billion

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

What matters in this story

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

What matters in this story

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

How each ticker is affected

Connected tickers

Track these names every morning.

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

XSPI: Inside The Boosted Option Book Going Into Q4

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

What matters in this story

Next reads from the same story arc

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

What matters in this story

Next reads from the same story arc

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

How each ticker is affected

Connected tickers

Track these names every morning.

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

XSPI: Inside The Boosted Option Book Going Into Q4